carbamates has been researched along with 2019 Novel Coronavirus Disease in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi)." | 4.02 | Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. ( Lankheet, NAG; Meussen, E; Mian, P; Piersma, D, 2021) |
| "Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2." | 3.11 | Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. ( Akpomiemie, G; Bosch, B; Casas, CP; Ellis, L; Hill, A; Johnstone, H; Owen, A; Simmons, B; Sokhela, S; Venter, WDF; Woods, J, 2022) |
| " Adverse events were evaluated in all patients who started their assigned treatment." | 3.01 | Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. ( Afsharian, M; Bozorgomid, A; Janbakhsh, A; Khodarahmi, R; Khosravi Shadmani, F; Mansouri, F; Miladi, R; Mohseni Afshar, Z; Najafi, F; Rahimi, Z; Salimi, M; Sayad, B; Shirvani, M; Vaziri, S; Zamanian, MH, 2021) |
| " All these compounds not only showed excellent pharmacokinetic properties, absorption, metabolism, minimal toxicity and bioavailability but were also remain stabilized at the active site of proteins during the MD simulation." | 1.56 | Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. ( Bhowmik, D; Jagadeesan, R; Kumar, D; Kumar, N; Nandi, R; Prakash, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 22 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsanni, A | 1 |
| Ma, J | 1 |
| Kaushik, D | 1 |
| Yeh, S | 1 |
| Northcutt, V | 1 |
| Babiak, J | 1 |
| Risher, N | 1 |
| Weetall, M | 1 |
| Moon, YC | 1 |
| Welch, EM | 1 |
| Molony, L | 1 |
| O'Keefe, K | 1 |
| Kong, R | 1 |
| Mobarak, S | 2 |
| Salasi, M | 1 |
| Hormati, A | 1 |
| Khodadadi, J | 1 |
| Ziaee, M | 1 |
| Abedi, F | 1 |
| Ebrahimzadeh, A | 1 |
| Azarkar, Z | 1 |
| Mansour-Ghanaei, F | 1 |
| Joukar, F | 1 |
| Yeganeh, S | 1 |
| Yaghubi Kalurazi, T | 1 |
| Naghipour, M | 1 |
| Mehrabi, Z | 1 |
| Bahadori, AR | 1 |
| Yaghoubi, S | 1 |
| Moslemi, R | 1 |
| Abbaspour Kasgari, H | 2 |
| Fakheri, H | 1 |
| Moghimi, M | 1 |
| Shabani, AM | 2 |
| Nekoukar, Z | 1 |
| Babamahmoodi, F | 2 |
| Davoudi Badabi, AR | 2 |
| Davoodi, L | 1 |
| Hassaniazad, M | 1 |
| Barahimi, E | 1 |
| Tousi, A | 1 |
| Sadeghi, A | 3 |
| Hosamirudsari, H | 1 |
| Ali Asgari, A | 2 |
| Abdollahi, M | 1 |
| Anushiravani, A | 1 |
| Shabani, M | 1 |
| Shokouhi, S | 1 |
| Khajavirad, N | 1 |
| Salehi, M | 1 |
| Dehghan Manshadi, SA | 1 |
| Mousavi, H | 1 |
| Zolfaghari, F | 1 |
| Azimi, E | 1 |
| Zeinali, A | 1 |
| Akbarpour, E | 2 |
| Merat, D | 1 |
| Eslami, G | 2 |
| Mousaviasl, S | 2 |
| Sayar, S | 1 |
| Radmanesh, E | 2 |
| Ebrahimzadeh, M | 1 |
| Arizavi, Z | 1 |
| Jelvay, S | 2 |
| Salmanzadeh, S | 2 |
| Esmaeilian, H | 2 |
| Mobarak, M | 2 |
| Karimi, J | 1 |
| Poormontaseri, Z | 1 |
| Hasooni Bahrini, N | 1 |
| Bonyadi, A | 1 |
| Dehghani, F | 1 |
| Mirzaei, H | 1 |
| Noori Jangi, M | 1 |
| Pourmasoomi, H | 1 |
| Rezaie Keikhaie, L | 1 |
| Afshari, M | 1 |
| Nateghi Baygi, A | 1 |
| Nateghi Baygi, H | 1 |
| Levi, J | 4 |
| McCann, K | 1 |
| Wentzel, H | 5 |
| Simmons, B | 5 |
| Hill, A | 6 |
| Merat, S | 4 |
| Sokhela, S | 1 |
| Bosch, B | 1 |
| Woods, J | 1 |
| Johnstone, H | 1 |
| Akpomiemie, G | 1 |
| Ellis, L | 1 |
| Owen, A | 2 |
| Casas, CP | 1 |
| Venter, WDF | 1 |
| Chen, YW | 2 |
| Yiu, CB | 2 |
| Wong, KY | 2 |
| Sayad, B | 2 |
| Sobhani, M | 1 |
| Khodarahmi, R | 2 |
| Izzi, A | 1 |
| Messina, V | 1 |
| Rinaldi, L | 1 |
| Maggi, P | 1 |
| Bhowmik, D | 1 |
| Nandi, R | 1 |
| Jagadeesan, R | 1 |
| Kumar, N | 1 |
| Prakash, A | 1 |
| Kumar, D | 1 |
| Iftikhar, H | 1 |
| Ali, HN | 1 |
| Farooq, S | 1 |
| Naveed, H | 1 |
| Shahzad-Ul-Hussan, S | 1 |
| Lens, S | 1 |
| Miquel, M | 1 |
| Mateos-Muñoz, B | 1 |
| García-Samaniego, J | 1 |
| Forns, X | 1 |
| Moradi, S | 1 |
| Davoudi, L | 1 |
| Alikhani, A | 1 |
| Hedayatizadeh Omran, A | 1 |
| Saeedi, M | 2 |
| Garratt, A | 2 |
| Tirgar Fakheri, H | 1 |
| Norouzi, A | 1 |
| Kheiri, Z | 1 |
| Anushirvani, A | 1 |
| Montazeri, M | 1 |
| Hosamirudsai, H | 1 |
| Afhami, S | 1 |
| Aliannejad, R | 1 |
| Radmard, AR | 1 |
| Davarpanah, AH | 1 |
| Qavi, A | 1 |
| Bitaraf, S | 1 |
| Freeman, J | 1 |
| Tabibi, R | 1 |
| Jafari Kashi, AH | 1 |
| Lotfi, Z | 1 |
| Talebzadeh, SM | 1 |
| Wickramatillake, A | 1 |
| Momtazan, M | 1 |
| Hajizadeh Farsani, M | 1 |
| Marjani, S | 1 |
| Ju, J | 2 |
| Li, X | 1 |
| Kumar, S | 1 |
| Jockusch, S | 2 |
| Chien, M | 2 |
| Tao, C | 2 |
| Morozova, I | 1 |
| Kalachikov, S | 1 |
| Kirchdoerfer, RN | 1 |
| Russo, JJ | 2 |
| Roozbeh, F | 1 |
| Alizadeh-Navaei, R | 1 |
| Hedayatizadeh-Omran, A | 1 |
| Shamshirian, A | 1 |
| Chan, HT | 1 |
| Chao, CM | 1 |
| Lai, CC | 1 |
| Mian, P | 1 |
| Meussen, E | 1 |
| Piersma, D | 1 |
| Lankheet, NAG | 1 |
| Spagnolo, F | 1 |
| Sacramento, CQ | 1 |
| Fintelman-Rodrigues, N | 1 |
| Temerozo, JR | 1 |
| Da Silva, APD | 1 |
| Dias, SDSG | 1 |
| da Silva, CDS | 1 |
| Ferreira, AC | 1 |
| Mattos, M | 1 |
| Pão, CRR | 1 |
| de Freitas, CS | 1 |
| Soares, VC | 1 |
| Hoelz, LVB | 1 |
| Fernandes, TVA | 1 |
| Branco, FSC | 1 |
| Bastos, MM | 1 |
| Boechat, N | 1 |
| Saraiva, FB | 1 |
| Ferreira, MA | 1 |
| Wang, X | 1 |
| Xie, W | 1 |
| Patel, D | 1 |
| Garzia, A | 1 |
| Tuschl, T | 1 |
| Rajoli, RKR | 1 |
| Pedrosa, CSG | 1 |
| Vitória, G | 1 |
| Souza, LRQ | 1 |
| Goto-Silva, L | 1 |
| Guimarães, MZ | 1 |
| Rehen, SK | 1 |
| Bozza, FA | 1 |
| Bou-Habib, DC | 1 |
| Bozza, PT | 1 |
| Souza, TML | 1 |
| Najafi, F | 1 |
| Miladi, R | 1 |
| Mohseni Afshar, Z | 1 |
| Mansouri, F | 1 |
| Rahimi, Z | 1 |
| Shirvani, M | 1 |
| Salimi, M | 1 |
| Vaziri, S | 1 |
| Janbakhsh, A | 1 |
| Khosravi Shadmani, F | 1 |
| Bozorgomid, A | 1 |
| Zamanian, MH | 1 |
| Afsharian, M | 1 |
| El-Bendary, M | 1 |
| Abd-Elsalam, S | 1 |
| Elbaz, T | 1 |
| El-Akel, W | 1 |
| Cordie, A | 1 |
| Elhadidy, T | 1 |
| Elalfy, H | 1 |
| Farid, K | 1 |
| Elegezy, M | 1 |
| El-Badrawy, A | 1 |
| Neamatallah, M | 1 |
| Abd Elghafar, M | 1 |
| Salama, M | 1 |
| AbdAllah, M | 1 |
| Essam, M | 1 |
| El-Shazly, M | 1 |
| Esmat, G | 1 |
| Begum, F | 1 |
| Srivastava, AK | 1 |
| Ray, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial[NCT04498936] | Phase 4 | 240 participants (Actual) | Interventional | 2020-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for carbamates and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbu | 2022 |
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Topics: Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Nitro Compounds; Pyrrolidines; SARS-CoV- | 2022 |
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Topics: Adult; Ambulatory Care; Antimalarials; Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatme | 2021 |
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Heterocyclic Compounds, 4 or More Rings; Humans; Iran | 2021 |
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.
Topics: Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; H | 2022 |
14 other studies available for carbamates and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; C | 2021 |
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbamates; Carbazoles; COVID-19; | 2022 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Clinical Trials as Topic; Coronavirus Infections; COV | 2020 |
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; DNA-Directed DNA Po | 2020 |
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Topics: Amides; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Binding Sites; Caffeic Acids; Carbam | 2020 |
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
Topics: Amides; Betacoronavirus; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus Infections; | 2020 |
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Topics: Antiviral Agents; Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dru | 2020 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dideoxynucleotides; | 2020 |
Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
Topics: Antiviral Agents; Carbamates; China; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbu | 2021 |
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; C | 2021 |
[Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.]
Topics: Aged; Benzimidazoles; Carbamates; COVID-19; Drug Combinations; Female; Humans; Melanoma; Skin Neopla | 2021 |
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Topics: Animals; Antiviral Agents; Carbamates; Chlorocebus aethiops; COVID-19; Humans; Imidazoles; Pharmaceu | 2021 |
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Topics: Amides; Antiviral Agents; Benzimidazoles; Carbamates; Catalytic Domain; Computer Simulation; Coronav | 2021 |